{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Charlotte&page=21&state=North+Carolina", "query": { "state": "North Carolina", "city": "Charlotte", "page": 21 }, "page_size": 10 }, "pagination": { "page": 21, "page_size": 10, "total_count": 953, "total_pages": 96, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Charlotte&page=22&state=North+Carolina&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Charlotte&page=20&state=North+Carolina&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-23T11:53:00.247Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT07195734", "title": "Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8", "Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8", "Locally Recurrent Head and Neck Squamous Cell Carcinoma", "Locally Recurrent Hypopharyngeal Squamous Cell Carcinoma", "Locally Recurrent Laryngeal Squamous Cell Carcinoma", "Locally Recurrent Oral Cavity Squamous Cell Carcinoma", "Locally Recurrent Oropharyngeal Squamous Cell Carcinoma", "Stage II Laryngeal Cancer AJCC v8", "Stage II Lip and Oral Cavity Cancer AJCC v8", "Stage II Oropharyngeal (p16-Negative) Carcinoma AJCC v8", "Stage III Laryngeal Cancer AJCC v8", "Stage III Lip and Oral Cavity Cancer AJCC v8", "Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8", "Stage IVA Laryngeal Cancer AJCC v8", "Stage IVA Lip and Oral Cavity Cancer AJCC v8", "Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8", "Stage IVB Laryngeal Cancer AJCC v8", "Stage IVB Oropharyngeal (p16-Negative) Carcinoma AJCC v8" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Cemiplimab", "type": "BIOLOGICAL" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Radiation Therapy", "type": "RADIATION" }, { "name": "Salvage Surgery", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL", "RADIATION" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 180, "start_date": "2026-04-24", "completion_date": "2033-02-01", "has_results": false, "last_update_posted_date": "2026-10-14", "last_synced_at": "2026-10-23T11:53:00.247Z", "location_count": 113, "location_summary": "Tucson, Arizona • Los Angeles, California • Palo Alto, California + 83 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07195734" }, { "nct_id": "NCT00444821", "title": "The (PIVOTAL) Study", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "ABDOMINAL AORTIC ANEURYSMS" ], "interventions": [ { "name": "AneuRx AAA stent graft / Talent AAA stent graft", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Medtronic Cardiovascular", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "40 Years to 90 Years" }, "enrollment_count": 728, "start_date": "2005-03", "completion_date": "2010-01", "has_results": true, "last_update_posted_date": "2021-10-11", "last_synced_at": "2026-10-23T11:53:00.247Z", "location_count": 65, "location_summary": "Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 57 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Escondido", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00444821" }, { "nct_id": "NCT01101438", "title": "A Phase III Randomized Trial of Metformin vs Placebo in Early Stage Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "metformin hydrochloride", "type": "DRUG" }, { "name": "placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Canadian Cancer Trials Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "74 Years", "sex": "ALL", "summary": "18 Years to 74 Years" }, "enrollment_count": 3649, "start_date": "2010-08-13", "completion_date": "2023-08-18", "has_results": true, "last_update_posted_date": "2023-09-13", "last_synced_at": "2026-10-23T11:53:00.247Z", "location_count": 280, "location_summary": "Anchorage, Alaska • Fairbanks, Alaska • Scottsdale, Arizona + 213 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Fairbanks", "state": "Alaska" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT01101438" }, { "nct_id": "NCT02057510", "title": "Observational Study of Dental Outcomes in Head and Neck Cancer Patients", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Head and Neck Cancer", "Dental Disease", "Xerostomia", "Osteoradionecrosis" ], "interventions": [], "intervention_types": [], "sponsor": "Wake Forest University Health Sciences", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 613, "start_date": "2014-02", "completion_date": "2020-01-28", "has_results": false, "last_update_posted_date": "2026-06-30", "last_synced_at": "2026-10-23T11:53:00.247Z", "location_count": 6, "location_summary": "Farmington, Connecticut • Boston, Massachusetts • New York, New York + 3 more", "locations": [ { "city": "Farmington", "state": "Connecticut" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" }, { "city": "Chapel Hill", "state": "North Carolina" }, { "city": "Charlotte", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT02057510" }, { "nct_id": "NCT03104413", "title": "A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Crohn's Disease Who Failed Prior Biologic Treatment", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Crohn's Disease" ], "interventions": [ { "name": "placebo for risankizumab IV", "type": "DRUG" }, { "name": "risankizumab SC", "type": "DRUG" }, { "name": "risankizumab IV", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "16 Years to 80 Years" }, "enrollment_count": 618, "start_date": "2017-12-18", "completion_date": "2021-05-19", "has_results": true, "last_update_posted_date": "2022-06-14", "last_synced_at": "2026-10-23T11:53:00.247Z", "location_count": 114, "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Tempe, Arizona + 89 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tempe", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03104413" }, { "nct_id": "NCT05388474", "title": "A Prospective and Retrospective Observational Study of Multidrug-Resistant Patient Outcomes With and Without Ibalizumab", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "HIV Infections", "Multi-Antiviral Resistance" ], "interventions": [ { "name": "No ibalizumab or Pre-ibalizumab treatment", "type": "OTHER" }, { "name": "On ibalizumab treatment", "type": "BIOLOGICAL" } ], "intervention_types": [ "OTHER", "BIOLOGICAL" ], "sponsor": "Theratechnologies", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 168, "start_date": "2022-03-22", "completion_date": "2026-07-02", "has_results": false, "last_update_posted_date": "2026-07-27", "last_synced_at": "2026-10-23T11:53:00.247Z", "location_count": 36, "location_summary": "Los Angeles, California • Palm Springs, California • San Diego, California + 22 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palm Springs", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT05388474" }, { "nct_id": "NCT01736618", "title": "S-ICD® System Post Approval Study", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Primary Prevention of Sudden Cardiac Arrest", "Secondary Prevention of Sudden Cardiac Arrest" ], "interventions": [ { "name": "S-ICD System", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Boston Scientific Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 1766, "start_date": "2013-03-12", "completion_date": "2021-10-15", "has_results": true, "last_update_posted_date": "2024-03-18", "last_synced_at": "2026-10-23T11:53:00.247Z", "location_count": 87, "location_summary": "Huntsville, Alabama • Mesa, Arizona • Phoenix, Arizona + 72 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT01736618" }, { "nct_id": "NCT00977574", "title": "Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Endometrial Adenocarcinoma", "Endometrial Adenosquamous Carcinoma", "Endometrial Clear Cell Adenocarcinoma", "Endometrial Serous Adenocarcinoma", "Recurrent Malignant Uterine Corpus Neoplasm", "Stage IIIA Uterine Corpus Carcinoma or Carcinosarcoma by AJCC v7 Stage", "Stage IIIB Uterine Corpus Carcinoma or Carcinosarcoma by AJCC v7 Stage", "Stage IIIC Uterine Corpus Carcinoma or Carcinosarcoma by AJCC v7 Stage", "Stage IVA Uterine Corpus Carcinoma or Carcinosarcoma by AJCC v7 Stage", "Stage IVB Uterine Corpus Carcinoma or Carcinosarcoma by AJCC v7 Stage" ], "interventions": [ { "name": "Bevacizumab", "type": "BIOLOGICAL" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Ixabepilone", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Temsirolimus", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 349, "start_date": "2009-09-14", "completion_date": "2027-03-06", "has_results": true, "last_update_posted_date": "2026-09-09", "last_synced_at": "2026-10-23T11:53:00.247Z", "location_count": 230, "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 163 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Burbank", "state": "California" }, { "city": "Concord", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00977574" }, { "nct_id": "NCT00408174", "title": "Balsalazide Disodium vs. Mesalamine in Mildly to Moderately Active Ulcerative Colitis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Inflammatory Bowel Disease", "Ulcerative Colitis" ], "interventions": [ { "name": "Balsalazide disodium", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bausch Health Americas, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 400, "start_date": "2006-05", "completion_date": "2007-11", "has_results": false, "last_update_posted_date": "2019-11-25", "last_synced_at": "2026-10-23T11:53:00.247Z", "location_count": 88, "location_summary": "Tempe, Arizona • Tucson, Arizona • Fayetteville, Arkansas + 74 more", "locations": [ { "city": "Tempe", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Anaheim", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00408174" }, { "nct_id": "NCT06953960", "title": "A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Surzetoclax", "type": "DRUG" }, { "name": "Daratumumab", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Pomalidomide", "type": "DRUG" }, { "name": "Etentamig", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 325, "start_date": "2025-07-23", "completion_date": "2030-12", "has_results": false, "last_update_posted_date": "2026-10-22", "last_synced_at": "2026-10-23T11:53:00.247Z", "location_count": 12, "location_summary": "Los Angeles, California • New Haven, Connecticut • Boston, Massachusetts + 9 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06953960" } ] }